Peer-reviewed veterinary case report
Chemo with doxorubicin and dacarbazine helps dogs
By Finotello, R et al.·Published in Veterinary and comparative oncology·2017·Department of Veterinary Clinics, Italy·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Comparison of doxorubicin-cyclophosphamide with doxorubicin-dacarbazine for the adjuvant treatment of canine hemangiosarcoma.
- Species:
- dog
Plain-English summary
A study involving dogs diagnosed with hemangiosarcoma, a serious type of cancer, compared two chemotherapy treatments: doxorubicin with cyclophosphamide and doxorubicin with dacarbazine. The results showed that dogs receiving the doxorubicin-dacarbazine combination lived longer and had a longer time before the cancer spread compared to those on the other treatment. Both treatment plans were well tolerated, meaning the dogs did not experience significant side effects. This suggests that the doxorubicin-dacarbazine combination could be a safer and more effective option for treating hemangiosarcoma in dogs.
People also search for: dog hemangiosarcoma treatment · doxorubicin side effects in dogs · canine cancer survival rates
Abstract
Canine hemangiosarcoma (HSA) is a neoplasm of vascular endothelial origin that has an aggressive biological behaviour, with less than 10% of dogs alive at 12-months postdiagnosis. Treatment of choice consists of surgery followed by adjuvant doxorubicin-based chemotherapy. We prospectively compared adjuvant doxorubicin and dacarbazine (ADTIC) to a traditional doxorubicin and cyclophosphamide (AC) treatment, aiming at determining safety and assessing whether this regimen prolongs survival and time to metastasis (TTM). Twenty-seven dogs were enrolled; following staging work-up, 18 were treated with AC and 9 with ADTIC. Median TTM and survival time were longer for dogs treated with ADTIC compared with those receiving AC (>550 versus 112 days, P = 0.021 and >550 versus 142 days, P = 0.011, respectively). Both protocols were well tolerated, without need for dose reduction or increased interval between treatments. A protocol consisting of combined doxorubicin and dacarbazine is safe in dogs with HSA and prolongs TTM and survival time.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/25623994/